Want to join the conversation?
$BAX 2Q15 Call: Within the fluid systems franchise sales $518MM declined 3% and on a constant currency basis sales advanced 3%. Performance was driven by re-launch of the CIGMA spectrum pump in the US and strong demand in favorable pricing for IV fluids. Sales in integrated pharmacy solutions franchise totaled $548MM and declined 16%.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.